Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs

Patent ExpiryAntibody-Based DrugsPositive

AI Analysis

Summary

Vesselon received a U.S. patent for compositions and methods enabling targeted delivery of antibody-based drugs with improved therapeutic index, achieving 6X more drug delivery to tumors with reduced off-target exposure.

Outcome Details

U.S. Patent Number 12,714,676 issued for compositions and methods for targeted delivery

Importance:4/10

Sentiment:

0.60

patentantibody therapeuticsdrug deliverytargeted therapy

Related Companies

$GLSI $CBDY $DMIIR

Read the original article

Published by PR Newswire Biotech on August 26, 2026 4:03 PM

Read Original